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Background: Vitamin A is a multifunctional vitamin that can inhibit the formation of Th17
cells, which are probably involved in the development of relapses in MS. Furthermore, it
promotes Treg formation. Therefore, vitamin A can be hypothesized to be lower in patients
than in healthy controls, and to decrease relapse risk in relapsing–remitting MS (RRMS) patients.
Objective: To compare vitamin A levels in MS patients and controls, and to investigate
whether vitamin A levels are associated with relapse risk.
Methods: In a case-control study all-trans-retinol levels were compared between 31 RRMS
patients and 29 matched controls.
In a prospective longitudinal study in 73 RRMS patients, serum samples for all-trans-retinol
measurements were taken every eight weeks. Associations between all-trans-retinol concentrations
and relapse rates were calculated using Poisson regression with the individual serum levels as time-
dependent variable. Associations between vitamin A and vitamin D were calculated.
Results: Mean vitamin A levels were lower in patients (2.16 μmol/l) than in controls (2.44 μmol/l)
but with borderline significance (p=0.05). In the longitudinal study, during follow-up (mean
1.7 years), 58 patients experienced a total of 139 relapses. Monthly moving averages of all-trans
retinol levels were categorized into tertiles: a low (o2.9 μmol/l), medium (2.9–3.7 μmol/l) and
high level (43.7 μmol/l). Relapse rates were not associated with serum all-trans retinol levels
(p40.2), in univariate nor in multivariate analysis.
Serum concentrations of all-trans-retinol and 25-OH-vitamin D were positively correlated, although
this correlation was weak (r=0.15).
Conclusion: We did not find evidence for a role for vitamin A in the disease course of RRMS. We
did find an association between vitamin A and D levels in the RRMS patients, possibly explained by
dietary products that contain both fat-soluble vitamins.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.13.06.011
hed by Elsevier B.V.
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35Vitamin A is not associated with exacerbations in multiple sclerosis1. Introduction Erasmus Medical Center University Hospital approved theVitamin A or retinol is a fat-soluble vitamin with multiple
functions, such as those in vision, growth and the normal
differentiation of epithelia (Wolf, 1996; Hall et al., 2011).
Over the last 2 decades, it has become clear that vitamin A
also has important roles in immune functioning, both in
immunological tolerance and in adaptive immune responses
(Hall et al., 2011).
After absorption from food, most vitamin A is stored in
the liver, from where it is added to the circulation bound to
retinol-binding protein (RBP) (Blomhoff and Blomhoff, 2006;
Theodosiou et al., 2010). Inside the target cells, retinol is
oxidized by alcohol dehydrogenase (ADH) into retinal, which
can then be oxidized into the active form retinoic acid (RA)
by the more selectively expressed retinaldehyde dehydro-
genase (RALDH) (Hall et al., 2011).
RA is a signaling molecule that can control gene expres-
sion, mainly through the activation of nuclear retinoid
receptors. There are three subgroups of retinoid receptors:
retinoic acid receptors (RARα-γ), retinoid X receptors
(RXRα-γ), and retinoic acid orphan receptors (RORα-γ)
(Hirahara et al., 2010). RXR can form heterodimers with
other nuclear receptors, such as vitamin D receptor (VDR)
(Theodosiou et al., 2010).
RA has been shown to inhibit the formation of Th17 cells,
which are probably involved in the development of relapses
in MS (Steinman, 2008), in vitro (Mucida et al., 2007) via
binding to RARα (Schambach et al., 2007; Elias et al., 2008).
It can do so synergistically with 1,25-diOH-vitamin D (Ikeda
et al., 2010). In EAE, a synthetic retinoid could also inhibit
Th17 cell differentiation and ameliorate EAE (Klemann
et al., 2009). Furthermore, RA can promote the formation
of anti-inflammatory Treg cells expressing Foxp3 (Coombes
et al., 2007; Mucida et al., 2007; Schambach et al., 2007).
Recently, it was also found that vitamin A is possibly
associated with MS risk (Salzer et al., 2013) and MRI
outcomes in MS (Loken-Amsrud et al., 2012).
Because of the roles described for vitamin A on Th17 and
Treg cells, we hypothesized that (1) vitamin A would be
lower in MS patients than in healthy controls, and (2) MS
patients with higher vitamin A levels would have a lower
relapse risk. To investigate this, we performed two studies:
a case-control study of vitamin A levels, and a prospective
longitudinal study of vitamin A levels in relapsing-remitting
MS (RRMS) patients to investigate the association between
vitamin A and relapse risk. Because of possible synergistic
effects, we also looked at the associations of vitamin A and
vitamin D in the longitudinal study.2. Patients and methods
2.1. Case control study on vitamin A and MS
2.1.1. Patients and controls
We randomly selected 31 patients with RRMS from our pool
of MS patients, subsequently selecting 29 controls matched
for age and sex. All controls had signed for informed
consent, and all patients were aware that serum would be
stored for later use. The Medical Ethical Committee of theuse of these materials.
2.1.2. Measurement of vitamin A
All-trans retinol was measured because this is the main form
of retinol in the circulation (Royal et al., 2002; Theodosiou
et al., 2010; Tanumihardjo 2012), and also the best measure
of vitamin A status. For analysis of retinol levels, the
samples were extracted with hexane and, after evapora-
tion, dissolved in methanol. Retinol levels were measured
through reverse-phase high-performance liquid chromato-
graphy (HPLC) (column: 150 4.8 mm, Polaris C18A, Waters
Alliance HT2795; detector: Waters 2475 [Waters, Milford,
MA]), with excitation at 328 nm and detection of emission at
468 nm. The intra-assay variability of retinol measurements
was 3.9% and the inter-assay variability was 5.1%.
2.1.3. Statistical analysis
Student’s T-test was used to compare mean all-trans retinol
levels between RRMS patients and healthy controls. ANOVA
was used to adjust for age. p=0.05 (two-sided) was
considered the limit of significance in all analyses. All
calculations were done using SPSS 20.0 for Windows.
2.2. Longitudinal study on vitamin A and
exacerbations
2.2.1. Patients
For the longitudinal study, data and samples were collected
in the Rotterdam Study on Exacerbations in MS, a prospec-
tive study in patients with relapsing-remitting MS (Buljevac
et al., 2002). Patients aged 18–55 years could be included in
the study if they had clinically definite MS with a relapsing-
remitting disease course and at least two exacerbations in
the previous 2 years. Patients were excluded from partici-
pation if they suffered from another serious disease. All
patients signed for informed consent. The study protocol
was approved by the Medical Ethical Committee of the
Erasmus Medical Center University Hospital.
2.2.2. Definitions
Exacerbation was defined as a worsening of existing symp-
toms or the appearance of new symptoms lasting for more
than 24 h after a period of more than 30 days of improve-
ment or stability, if confirmed by neurologic examination
(Schumacker et al., 1965). A temporary neurological dete-
rioration associated with fever was not considered to be an
exacerbation.
Because infection is a known risk factor for exacerbations
in multiple sclerosis, the ‘at risk period’ around infection
was used as a covariate in this study, as described previously
(Buljevac et al., 2002).
2.2.3. Visits, samples and measurement of
exacerbations
All patients visited the outpatient clinic of the Erasmus
Medical Centre University Hospital regularly every 8 weeks.
At every visit, blood samples were taken and disability was
measured using the Kurtzke Expanded Disability Status Scale
(EDSS) (Kurtzke, 1983). In the event of a suspected exacer-
bation or infection, additional visits were arranged within
Table 1 Characteristics of patients and controls of the case-control study.
Characteristic Patients SD Controls SD
Sex (f/m) 22/7 24/7
Age mean (range) 35.4 (19–56) 10.3 35.9 (19–56) 10.4
Ethnicity (%)
White caucasion 77.4 89.7
Mediterranean 16.1 10.3
Black 6.5
Disease duration (years) mean (range) 4.5 (0–29) 5.4
Fig. 1 Serum all-trans retinol concentrations of relapsing-
remitting MS patients and healthy controls.
T.F. Runia et al.363 days. Serum samples were stored at −80 1C until serum
vitamin A measurement.
2.2.4. Measurement of vitamin A and vitamin D
Measurements of all-trans retinol were as described above.
To investigate the association between vitamin A and D, we
used a RIA method (DiaSorin, USA) using an extraction
method, to measure 25-OH-vitamin D levels. The inter-
assay variation coefficient at a concentration of 62 nmol/L
was 11.6%; at 109 nmol/L it was 10.3%. The respective
intra-assay variation coefficients at these levels were
5.7 and 6.6%. Only serum samples taken at the regular
eight-weekly visits were used for the measurement of all-
trans retinol and 25-OH-vitamin D; samples taken during
exacerbation visits were not evaluated.
2.2.5. Statistical analysis
To assess the association between individual serum all-trans
retinol concentrations and the incidence rate of exacerba-
tions, we split the follow-up time for each patient, which
covered a maximum period of 2.3 years, into intervals of
one week each. The number of exacerbations was deter-
mined for each of these intervals. The individual exacerba-
tion rate was assumed to depend on the mean serum all-
trans retinol concentration over the previous 4 weeks. To
obtain this mean level, the weekly levels between measure-
ments were determined per individual using interpolated
values. These interpolated values were subsequently aver-
aged. During the period of 4 weeks that followed an
exacerbation, an individual was not considered to be at
risk for another exacerbation. It was decided a priori to
categorize the mean serum levels of the 4 preceding weeks
into tertiles: low (o2.9 μmol/l), medium (2.9–3.7 μmol/l)
and high (43.7 μmol/l). The relationship between serum
all-trans retinol concentrations and the incidence rate of
exacerbations was assessed using the Poisson regression
models with the mean individual serum levels as a time-
dependent variable. In the calculations we used generalized
estimating equations with an exchangeable covariance
matrix for the subsequent study weeks. The effect of other
factors, including gender, age, EDSS, number of exacerba-
tions before study entry and use of interferon-β during the
study, was also estimated using a multivariable generalized
linear model with a log-link function. Associations between
measured vitamin A and vitamin D concentrations, the
latter log-transformed to get an approximate normal dis-
tribution, were calculated using mixed model regressionanalysis for repeated measurements. p=0.05 (two-sided)
was considered the limit of significance in all analyses. All
calculations were done using SPSS 20.0 for Windows.3. Results
3.1. Case control study on vitamin A
concentrations and MS
3.1.1. Patient characteristics
The baseline characteristics of the 31 patients and 29
controls included are shown in Table 1. We had no informa-
tion on the use of vitamin supplements of patients and
controls. None of the patients were using interferon β at the
time of blood sampling, because sampling was done during a
clinical workup for therapy advice within our MS center.3.1.2. Serum vitamin A concentrations
For most patients and controls, serum all-trans retinol
concentrations fell within the normal range. None of the
patients and none of the controls were vitamin-A deficient.
As Fig. 1 shows, all-trans retinol concentrations where
somewhat lower in patients than in controls (mean
2.1670.55 μmol/l vs. 2.4470.52 μmol/l), but this differ-
ence was only borderline significant (p=0.050). Vitamin A
depended on age in the case-control study, but not in the
longitudinal study. It did not depend on sex. When adjusting






Age, years 39.4 (19–55) 9.1
Disease duration, years 5.2 (0–25) 4.1







IFN use, N/Y 82/18
aEDSS is a method for quantifying disability in MS, ranging
from 0.0 (normal neurological exam) to 10.0 (death due to MS).
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patients and controls (p=0.070).3.2. Longitudinal study on vitamin A and
exacerbations
3.2.1. Patient characteristics
73 patients were included in this study. The mean follow-up
time of all patients was 1.7 years (range 0.4–2.3). Nine
patients had dropped out of the study before the intended
completion date, one due to participation in another study,
the other eight for unknown reasons. All patients were
Dutch Caucasians; their baseline characteristics are shown
in Table 2. In addition to the 13 patients who used
interferon-β at study entry, 15 started to use interferon-β
during follow-up; these 28 patients used interferon-β at
some point during an average of 56 weeks. Vitamin supple-
ments were not widely used among the patients: five used
vitamin B complex (without vitamin A) and two used multi-
vitamin pills, one of which contained 6 mg of beta-
carotene.
58 patients experienced a total of 139 exacerbations
during this study. Median time from inclusion to first
exacerbation was 20 weeks. Thirty-three patients had more
than one exacerbation; the average exacerbation rate was
1.2 per year (range 0–6.2 per year). Three patients experi-
enced a sixth exacerbation during follow-up.3.2.2. Serum vitamin A concentrations
Serum all-trans retinol concentrations fluctuated consider-
ably, without a seasonal pattern or other clear pattern. Mean
serum all-trans retinol concentration was 3.3171.14 μmol/l.
Mean levels varied substantially between patients (Anova:
Po0.001). Within patients there was also a considerable
variation between measurement occasions. Of the total
variation in levels 40% was due to differences between
patients while 60% was due to differences within patients.3.2.3. Association between serum vitamin A
concentrations and exacerbation risk
Univariate analysis did not show exacerbation rates to be
associated with serum all-trans retinol levels (p40.2).
As shown previously(Runia et al., 2012), infections were
associated with the risk of an exacerbation, the exacerba-
tion rate within an “at risk period” being 2.1-fold higher
(95% CI 1.6 to 2.8, Po0.001). Also, vitamin D (25-OH-D)
serum levels were found to be associated with exacerbation
risk. In the multivariate model including 25-OH-D and
infections, infections and 25-OH-D were both still related
to the exacerbation rate, whereas all-trans retinol was not
(Table 3). Adding gender or the use of interferon-β to the
model did not alter these results. Also age, EDSS and the
number of exacerbations in the 2 year period before entry
into the study were not significantly associated with the
exacerbation rates (all p40.18).
3.2.4. Association between vitamin A and vitamin D
Serum concentrations of all-trans retinol and 25-OH-D had a
significant linear correlation. Mixed model regression ana-
lysis showed that for every doubling of serum 25-OH-D
concentration the mean all-trans retinol level increased by
0.59 μmol/l (Po0.001). The correlation however was weak
(r=0.15).
4. Discussion
This case-control study shows that vitamin A concentrations
are not significantly lower in MS patients than in healthy
controls. Our longitudinal study also shows that vitamin A is
not associated with relapse risk in MS patients. We also
found that vitamin A and vitamin D were associated in a
linear manner.
There are several reasons to hypothesize that vitamin A is
involved in MS. In the past, it has been hypothesized that
the susceptibility period in multiple sclerosis lies in early
childhood (Pugliatti et al., 2006) and that the element
responsible was (a deficiency in) vitamin A (Warren, 1982).
This hypothesis was based mainly on epidemiological evi-
dence, and the mechanisms through which vitamin A
deficiency was thought to cause MS were effects on normal
CNS myelination and effects on skull and bone growth
affecting normal CNS growth. Since knowledge of the
functions of vitamin A in immunity has grown in the last
decades (Hall et al., 2011) (inhibiting Th17 cell formation
(Mucida et al., 2007) and promoting Treg formation
(Coombes et al., 2007; Mucida et al., 2007; Schambach
et al., 2007)), the hypothesis that vitamin A might be
involved in the development and disease course of MS has
become stronger. Recently, it was also found that RXR
agonists can stimulate remyelination (Huang et al., 2011).
Vitamin A has even been suggested as a (supplementary)
treatment option in MS (Royal et al., 2002; Klemann et al.,
2009). However, in the present case-control and longitudi-
nal studies we cannot provide any evidence that vitamin A is
really involved in MS.
In the case-control study, we found somewhat lower
retinol concentrations in patients than in controls, but this
was not significant. Other studies that addressed this topic
had conflicting results. One study also did not find lower
Table 3 Association between exacerbation rate and categorized serum all-trans retinol concentrations according to the
multivariable analysis including infection and 25-OH-vitamin D concentrations. ARP infection=at risk period for infection.
Relative exacerbation rate 95% CI P-value
All-trans retinol concentrations Low o2.9 μmol/l 1.2 0.8–1.8 0.329a
Medium 2.9–3.7 μmol/l 1.3 0.8–1.9 0.254a
High 43.7 μmol/l 1 (reference) – –
ARP infection Yes 1 (reference) – –
No 0.4 0.3–0.6 o0.001
25-OH-D concentrations Low o50 nmol/l 2.0 1.2–3.4 0.012b
Medium 50–100 nmol/l 1.3 0.8–2.2 0.281b
High 4100 nmol/l 1 (reference) – –
aOverall p-value: 0.489.
bp-value for trend: 0.010.
T.F. Runia et al.38levels than in controls (de Bustos et al., 2000). Another
study found lower levels in MS patients than in controls
(Besler et al., 2002). Differences with our study were that
all patients had a secondary progressive disease course, and
that a different technique was used for the measurements
(Neeld–Pearson with trifluoroacetic acid instead of HPLC). A
third study compared retinol levels in patients and controls,
finding significant differences only between subgroups
(Royal et al., 2002). It should be noted that in that study
retinol levels were slightly higher in interferon-β treated
patients.
The borderline significance in our results suggests that our
groups might have been too small. On the other hand, as
Fig. 1 shows, the mean levels of vitamin A in patients and
controls are not far apart, and confidence intervals are wide,
suggesting substantial variation within the patient and con-
trol group. In our longitudinal study, we also found substan-
tial within-patient variation of retinol levels. We found that
vitamin A was also dependent on age, which has been
described before by Looker et al. (1988) but was not found
by Hallfrisch et al. (1994). Because our control group was
age- and sex matched, this has not influenced our
conclusions.
In the longitudinal study we found no association
between vitamin A and exacerbation rate. One recent study
using the same technique for retinol assessment, found an
inverse association between new lesion formation on MRI
and vitamin A levels (Loken-Amsrud et al., 2012). We could
not confirm an association between vitamin A and clinical
disease activity in MS in our study. But although our long-
itudinal study with its frequent serum sampling provides a
robust way of studying this topic, the fact that we found no
association does not totally exclude a role for vitamin A in
MS relapses. There might be local function or production of
RA in the CNS associated with relapses, that cannot be
measured systemically, for example by tissue-specific
expression of retinoid receptors or retinaldehyde dehydro-
genase (RALDH) (Hall et al., 2011).
A limitation of our study is that none of the patients in
the case-control study used interferon-β. In the longitudinal
study, the use of interferon-β did not influence our results.
In studies by others on this topic conflicting results havebeen found: some found a synergistic effect of RA with
interferon-β on T suppressor cell augmentation (Qu et al.,
1998), others found the association between vitamin A and
MRI outcomes to be non-significant during interferon-β use
(Loken-Amsrud et al., 2012). We were unable to confirm any
of this here.
We found an association between serum levels of vitamin
A and D. Vitamin A can be absorbed from food, but its levels
can also be increased via a rise in hepatic production as a
result of exposure to light (Pang et al., 2008; Mehta, 2010).
Because vitamin D is also a fat-soluble vitamin that can be
absorbed from food and can also be synthesized under the
influence of sun light, it is not surprising that the concen-
trations of both vitamins increase and decrease simulta-
neously. However, we did not find synergistic action in this
study: whereas a higher vitamin D level was associated with
a lower relapse risk, vitamin A was not.
For our analyses of retinol levels, we used random serum
samples and not fasting samples. This is justified because
retinol is derived from hepatic and other body stores and is
a good measure of vitamin-A status, unlike retinyl-esters,
which are absorbed after a vitamin-A rich meal (Royal
et al., 2002).
In recent years, several studies on the relation between
vitamin A and MS have been performed, using different
techniques and markers, sometimes with conflicting results
(de Bustos et al., 2000; Besler et al., 2002; Royal et al., 2002;
Munger et al., 2004; Loken-Amsrud et al., 2012; Salzer et al.,
2013). Routine measurement of vitamin A and carotenoids is
now generally done using high performance liquid chromato-
graphy (HPLC). Lately, the use of plasma RBP as a surrogate
marker for retinol is increasing. It should be realized that this
is only valid in the absence of infection or when adjusted for
CRP levels (2012; Salzer et al., 2013).
In conclusion, there are several reasons to hypothesize
that vitamin A has a role in the development and disease
course of MS. Here we did not observe differences in retinol
levels between patients and controls. In addition, in the
prospective study on exacerbations, we found no associa-
tion with disease activity. These results do not feed the
perception that vitamin A could be a useful treatment for
MS patients (Royal et al., 2002; Klemann et al., 2009).
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